{
    "clinical_study": {
        "@rank": "92509", 
        "acronym": "OCCLUDE-II", 
        "brief_summary": {
            "textblock": "To collect confirmatory data in support of the safety and performance of the ArtVentive\n      Medical Group Endoluminal Occlusion System."
        }, 
        "brief_title": "Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemorrhage", 
            "Bleeding"
        ], 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "detailed_description": {
            "textblock": "Prospective, non-randomized, multi-center confirmatory observational study for the treatment\n      of subjects with the need for vascular occlusion for the following conditions:\n\n        1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury\n\n        2. Hemorrhage caused by a neoplasia\n\n        3. Neoplastic process (tumor)\n\n        4. Gastrointestinal bleeding\n\n        5. Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous\n           malformations or an arteriovenous fistula\n\n        6. Interrupting blood supply to an organ or part of an organ for permanent\n           devascularization\n\n        7. Devascularization of tissues involved by a neoplastic process either pre-operatively or\n           as a palliative measure\n\n        8. Transjugular Intrahepatic Portosystemic Shunt (TIPS)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects aged \u226518 to \u226475 years.\n\n          2. Subject with target vessels of 3.0 mm to 12 mm in diameter.\n\n          3. Subject is able and willing to comply with all study requirements, including the\n             required study follow-up visits.\n\n          4. Subject or subject's legal representative have been informed of the nature of the\n             study, agrees to participate and has signed the consent form.  In the event of\n             emergency procedure and subject and/or legal representative is unable to provide\n             consent prior to study enrollment, consent will be obtained at earliest possible time\n             following procedure for consent to continue to participate in the study.\n\n        Exclusion Criteria:\n\n          1. Subject has a known allergy to iodinated contrast for which they cannot be adequately\n             premedicated.\n\n          2. Subjects in whom venography or arteriography is contraindicated.\n\n          3. Subjects with known hypersensitivity or contraindication to nickel or nitinol.\n\n          4. Subject is pregnant or breastfeeding.\n\n          5. Any clinical evidence that the investigator feels would place the subject at\n             increased risk with the deployment of the device."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects requiring permanent occlusion of the peripheral vessels for the following\n        conditions:\n\n          1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury\n\n          2. Hemorrhage caused by a neoplasia\n\n          3. Neoplastic process (tumor)\n\n          4. Gastrointestinal bleeding\n\n          5. Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous\n             malformations or an arteriovenous fistula\n\n          6. Interrupting blood supply to an organ or part of an organ for permanent\n             devascularization\n\n          7. Devascularization of tissues involved by a neoplastic process either pre-operatively\n             or as a palliative measure.\n\n          8. Transjugular Intrahepatic Portosystemic Shunt (TIPS)"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033954", 
            "org_study_id": "TD 0088 / 02"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Embolization", 
            "Hemorrhage", 
            "TIPS", 
            "GI Bleeding", 
            "AV Fistula", 
            "AV Malformation", 
            "Traumatic Vascular Injury"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Peter.waldenberger@bhs.at", 
                    "last_name": "Peter Waldenberger, Prof Dr", 
                    "phone": "+43 73276777346"
                }, 
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria"
                    }, 
                    "name": "Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H."
                }, 
                "investigator": {
                    "last_name": "Peter Waldenberger, Prof Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "geert.maleux@uzleuven.be", 
                    "last_name": "Geert Maleux, Prof Dr", 
                    "phone": "+32 16 34 37 82"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Leuven"
                }, 
                "investigator": {
                    "last_name": "Geert Maleux, Prof Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "radiologie@uniklinikum--dresden.de", 
                    "last_name": "Ralf Hoffmann, PD Dr.", 
                    "phone": "+49 351 - 458 2259"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "Universitatsklinikum Carl Gustav Carus Institut"
                }, 
                "investigator": {
                    "last_name": "Ralf Hoffmann, PD Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.treitl@med.unimuenchen.de", 
                    "last_name": "Andreas Mahnken, Prof Dr", 
                    "phone": "+49 6421 58-66231"
                }, 
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4tsklinikum Giessen und Marburg (UKGM) Klinik f\u00fcr diagnostische und"
                }, 
                "investigator": {
                    "last_name": "Andreas Mahnken, Prof Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "m.treitl@med.unimuenchen.de", 
                    "last_name": "Marcus Treitl, Prof dr", 
                    "phone": "+49 89-5160-9271"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "LMU Klinikum der Universit\u00e4t M\u00fcnchen, Campus Innenstadt, Interventionelle Radiologie"
                }, 
                "investigator": {
                    "last_name": "Marcus Treitl, Prof Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Germany"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding - OCCLUDE II", 
        "overall_contact": {
            "email": "leonrudakov@artventivemedical.com", 
            "last_name": "Leon Rudakov, PhD", 
            "phone": "+1 (760) 471-7700"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e4tsklinikum Giessen und Marburg (UKGM) Klinik f\u00fcr diagnostische und", 
            "last_name": "Andreas Mahnken, Prof Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Ethikkommission", 
                "Germany: Ethics Commission", 
                "Belgium: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of new-onset major device-related adverse event(s) including device embolization beyond targeted treatment area (not therapeutic indication of embolization), need for emergency surgical intervention of the target vessel, or distal embolization (non-device embolization, e.g., particulate matter / plague distal to the device) at 30 days.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Acute & 30 days"
        }, 
        "reference": {
            "PMID": "23703667", 
            "citation": "Venbrux AC, Rudakov L, Plass A, Emmert MY, Ebner A. A New Occlusion Device: Application of the ArtVentive Endoluminal Occlusion System (EOS)-First in Human Clinical Trial. Cardiovasc Intervent Radiol. 2013 May 24. [Epub ahead of print]"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033954"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Sustained occlusion at 30 days follow-up.", 
            "measure": "Occlusion", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "source": "ArtVentive Medical Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ArtVentive Medical Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "30 Days", 
        "verification_date": "January 2014"
    }
}